Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2000
09/08/2000WO2000052007A1 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
09/08/2000WO2000052005A1 Febrifugine and isofebrifugine and processes for the preparation of both
09/08/2000WO2000051991A1 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES
09/08/2000WO2000051988A1 Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity
09/08/2000WO2000051986A1 Cyclopentanone dihydropyridine compounds useful as potassium channel openers
09/08/2000WO2000051982A1 N-substituted indolines as estrogenic agents
09/08/2000WO2000051981A1 Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
09/08/2000WO2000051979A1 C16 unsaturated fp-selective prostaglandins analogs
09/08/2000WO2000051978A1 Nitrosated and nitrosylated prostaglandins, compositions and metods of use
09/08/2000WO2000051975A1 Alkenyl- and alkynyl-containing metalloprotease inhibitors
09/08/2000WO2000051972A1 1,2,3,4-tetrahydro-1-naphthalenamine compounds useful in therapy
09/08/2000WO2000051971A1 Oxamic acids and derivatives as thyroid receptor ligands
09/08/2000WO2000051970A1 Amide compounds for the potentiation of cholinergic activity
09/08/2000WO2000051968A1 Method for the preparation of a chiral-beta-amino ester
09/08/2000WO2000051959A1 Fluorinated chalcone derivatives or salts thereof and drugs containing the same as the active ingredient
09/08/2000WO2000051718A1 Chemical method for making pyrithione particle dispersions
09/08/2000WO2000051686A1 Use of integrin antagonist and a chemotherapeutic agent in the treatment of neoplasia
09/08/2000WO2000051685A1 Composition comprising a tramadol material and a selective cox-2 inhibitor drug
09/08/2000WO2000051684A2 Regulators of coenzyme-a-independent transacylase as psychotropic drugs
09/08/2000WO2000051644A1 TREATMENT OF DIARRHEA CAUSED BY ENTEROPATHOGENIC $i(ESCHERICHIA COLI)
09/08/2000WO2000051643A1 Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
09/08/2000WO2000051642A1 Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease
09/08/2000WO2000051641A1 Pharmaceutical combination of antiviral agents
09/08/2000WO2000051640A1 Itchiness-relieving agents and itchiness-relieving effect potentiators
09/08/2000WO2000051634A1 Vaccine preparations containing fatty acids as constituent
09/08/2000WO2000051629A1 Preparations stabilized over long time
09/08/2000WO2000051622A1 Drugs containing sulfopyranosylacylglycerol derivatives
09/08/2000WO2000051620A1 Agents for intravitreal administration to treat or prevent disorders of the eye
09/08/2000WO2000051618A1 (ANDROST-5-EN-17β-YL)ALKYL SULFOXIDES AND SULFONES AND THEIR USE FOR CONTROL OF FERTILITY
09/08/2000WO2000051617A1 Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds
09/08/2000WO2000051616A1 Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
09/08/2000WO2000051615A1 Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
09/08/2000WO2000051612A1 Inhibitors of prenyl-protein transferase
09/08/2000WO2000051611A1 Inhibitors of prenyl-protein transferase
09/08/2000WO2000051608A1 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
09/08/2000WO2000051606A1 Use of remifentanyl for reducing blood pressure
09/08/2000WO2000051605A1 Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids
09/08/2000WO2000051604A1 Intermittent claudication remedies
09/08/2000WO2000051603A2 Compositions of remifentanil
09/08/2000WO2000051602A1 Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity
09/08/2000WO2000051601A1 Immunopotentiators
09/08/2000WO2000051599A1 Method for treating exercise induced asthma
09/08/2000WO2000051598A1 Method for treating copd
09/08/2000WO2000051597A1 Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss
09/08/2000WO2000051596A1 Antithrombotic use of glycine betaine
09/08/2000WO2000051595A1 Methods and compositions for the treatment of neuropathic pain, tinnitus, and other disorders using r(-)-ketoprofen
09/08/2000WO2000051594A1 Use of succinic acid or salts thereof and method of treating insulin resistance
09/08/2000WO2000051593A2 Oral drug delivery system
09/08/2000WO2000051592A1 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
09/08/2000WO2000051591A1 Combinations of formoterol and mometasone furoate for asthma
09/08/2000WO2000051590A2 Neuropharmacological treatment of sleep-related breathing disorders
09/08/2000WO2000051589A2 VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF
09/08/2000WO2000051587A2 Jak-3 inhibitors for treating allergic disorders
09/08/2000WO2000051586A2 Treating a variety of pathological conditions, including spasticity and convulsions, by effecting modulation of cns activity with isovaleramide, isovaleric acid, or a related compound
09/08/2000WO2000051585A2 Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
09/08/2000WO2000051584A2 Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
09/08/2000WO2000051583A2 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
09/08/2000WO2000051582A2 Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
09/08/2000WO2000051581A2 Hydroxy-halo-quinazolines for augmentation of mast cell bactericidal activity
09/08/2000WO2000051579A2 Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity
09/08/2000WO2000051578A2 Use of ceramides for the treatment of cystic fibrosis
09/08/2000WO2000051577A2 Use of fluorinated triazoles for treating pain and affective or attention disorders
09/08/2000WO2000051576A2 Novel pharmaceuticals, dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation, hypersensitivity reactions or pain
09/08/2000WO2000051575A1 Transdermal device comprising non-steroidal anti-inflammatory drugs incorporated in acrylic adhesive polymer matrix
09/08/2000WO2000051571A2 Capsule system
09/08/2000WO2000051566A1 Scar reduction
09/08/2000WO2000051564A1 Echinocandin pharmaceutical formulations containing micelle-forming surfactants
09/08/2000WO2000051563A1 Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter
09/08/2000WO2000051562A1 Matrix metalloprotease inhibitor and utilization thereof
09/08/2000WO2000051561A1 Cosmetics
09/08/2000WO2000051557A1 Aerosol hair spray compositions comprising combinations of silicone-grafted copolymers
09/08/2000WO2000051549A1 Dermatological compositions containing a liquid crystal vehicle and method of preparing same
09/08/2000WO2000051548A2 COMPOSITIONS AND METHODS FOR THEIR PREPARATION FROM $i(LEPIDIUM)
09/08/2000WO2000051547A2 Inhibitors of prenyl-protein transferase
09/08/2000WO2000051546A2 Bupropion metabolites and methods of their synthesis and use
09/08/2000WO2000051539A1 Opioid agonist in a fast dispersing dosage form
09/08/2000WO2000051444A1 Utilization of material containing docosapentaenoic acid
09/08/2000WO2000037472A3 Substituted pirroloindoles
09/08/2000WO2000034260A3 Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
09/08/2000WO2000027418A3 A method for treating tissue damaged from ischemia
09/08/2000WO2000027414A3 Inhibition of the formation of vascular hyperpermeability
09/08/2000WO2000027341A3 Novel method of treatment
09/08/2000WO2000026174A3 Process for preparing natural product derivatives from plants in a single step
09/08/2000WO2000025754A3 Solid oral dosage forms containing alginic acid and famotidine
09/08/2000WO2000024361A3 Bis(haloethyl)aminobenzene derivatives
09/08/2000WO2000023060A3 Method of treating immunological disorders mediated by t-lymphocytes
09/08/2000WO2000021547A3 Utilization of proteolytic enzymes to influence hyperactive t cells
09/08/2000WO2000019883A3 Compositions and methods of disease diagnosis and therapy
09/08/2000WO2000019206A9 Ykl-40 as a marker and prognostic indicator for cancers
09/08/2000WO2000018212A9 Platelet-derived growth factor c, dna coding therefor, and uses thereof
09/08/2000WO2000016756A3 Use of n-acylvanillinamide derivatives as agonists of peripheral cannabinoid cb1 receptors
09/08/2000WO2000012720A3 Elongase genes and uses thereof
09/08/2000WO2000012497B1 Quinazoline derivatives as medicaments
09/08/2000WO2000010526A3 New oral formulation for 5-ht4 agonists or antagonists
09/08/2000WO2000007583A3 Treatment of addiction and addiction-related behavior
09/08/2000WO2000007579A3 Use of cyclopentabenzofuran-derivatives for combating nf-$g(k)b-dependent diseases
09/08/2000WO1999060987A9 Control of pain with endogenous cannabinoids
09/08/2000WO1999034784A3 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis
09/08/2000CA2373463A1 Intermittent claudication remedies
09/08/2000CA2371822A1 Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
1 ... 6249 6250 6251 6252 6253 6254 6255 6256 6257 6258 6259 6260 6261 6262 6263 6264 6265 6266 6267 6268 6269 ... 7860